Clinical Trials Directory

Trials / Completed

CompletedNCT00650325

Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg

Single-Dose Fasting In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
49 (actual)
Sponsor
Mylan Pharmaceuticals Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administered under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGSertraline Hydrochloride Tablets 100 mg100mg, single dose fasting
DRUGZoloft® Tablets 100 mg100mg, single dose fasting

Timeline

Start date
2002-11-01
Primary completion
2002-12-01
Completion
2002-12-01
First posted
2008-04-01
Last updated
2024-04-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00650325. Inclusion in this directory is not an endorsement.

Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg (NCT00650325) · Clinical Trials Directory